PT-141
Also known as: Bremelanotide · Bremelanotida · PT-141 FREE BASE
PT-141 is bremelanotide, a melanocortin receptor agonist and an FDA-approved prescription drug marketed as Vyleesi. Research-grade PT-141 is used strictly for laboratory and preclinical studies focused on sexual function and melanocortin receptor pharmacology, distinct from the approved pharmaceutical formulation.
What is PT-141?
PT-141, also known as bremelanotide, is a synthetic peptide that functions as an agonist at melanocortin receptors, particularly MC3R and MC4R, which are predominantly expressed in the central nervous system. It is structurally related to alpha-melanocyte stimulating hormone (alpha-MSH) and was developed to explore therapeutic avenues in sexual dysfunction.
Originally derived from modifications of naturally occurring melanocortin peptides, PT-141 was designed to selectively target central nervous system pathways involved in sexual arousal and erectile function. This peptide has been investigated extensively in preclinical models and clinical trials due to its unique mechanism of action compared to traditional treatments for sexual dysfunction.
In research contexts, PT-141 is employed to study the neurophysiological regulation of sexual behavior and erectile function, with a focus on its ability to activate neurons in the hypothalamus and associated brain regions. It is important to distinguish between PT-141 as a research compound and its FDA-approved pharmaceutical form, which is marketed under the name Vyleesi for specific clinical indications.
Researchers continue to investigate PT-141 to better understand melanocortin receptor signaling pathways and to explore potential applications in sexual dysfunction and related neurological processes.
Key Benefits & Mechanisms
- Erectile Dysfunction ResearchPT-141 has been studied extensively in preclinical and clinical settings for its ability to induce erectile responses. Activation of central melanocortin receptors by PT-141 leads to neuronal signaling that facilitates erectile function, making it a valuable tool for investigating novel treatments for erectile dysfunction.
- Female Sexual DysfunctionBeyond male sexual dysfunction, PT-141 has been evaluated for its effects on female sexual arousal and desire. Research explores its capacity to modulate central neural circuits implicated in sexual motivation and behavior, offering insights into potential therapies for female sexual dysfunction.
- Central Nervous System ModulationPT-141’s selective agonism at MC3R and MC4R in the brain allows researchers to probe the roles of these receptors in regulating complex behaviors, including appetite, energy homeostasis, and sexual function. This makes PT-141 a versatile compound in neuropharmacological research.
- Neuronal Activation StudiesStudies using PT-141 have demonstrated increased c-Fos immunoreactivity in hypothalamic neurons, indicating activation of specific brain regions. This property aids in mapping neural pathways involved in sexual function and understanding receptor-mediated neuronal activation mechanisms.
Mechanism of action
PT-141 acts as a potent agonist at melanocortin receptors MC3R and MC4R, which are G protein-coupled receptors primarily expressed in the central nervous system, particularly in hypothalamic regions. Upon binding, PT-141 activates these receptors, leading to neuronal excitation and downstream signaling cascades that facilitate sexual arousal and erectile function. This activation results in dose-dependent increases in erectile activity observed in animal models and human subjects, distinct from peripheral vasodilatory mechanisms. The central nervous system targeting differentiates PT-141 from other erectile dysfunction agents, highlighting its unique neuropharmacological profile.
Research Summary
Research on PT-141 has primarily focused on its role as a melanocortin receptor agonist in sexual dysfunction. One 2003 study titled "PT-141: a melanocortin agonist for the treatment of sexual dysfunction" demonstrated that PT-141 administration in rats and nonhuman primates elicited penile erections through activation of hypothalamic neurons, as evidenced by increased c-Fos immunoreactivity. The study further showed that systemic PT-141 induced rapid, dose-dependent erectile responses in both healthy men and patients with erectile dysfunction, suggesting its therapeutic potential.
Another abstract from 2004, "PT-141 Palatin.", describes Palatin’s development of PT-141 as a nasal spray formulation targeting erectile dysfunction and female sexual dysfunction. The company completed phase IIb clinical trials by 2003 and planned phase III trials by 2005, underscoring the translational research efforts moving PT-141 from preclinical into clinical domains.
- PT-141 Palatin. (2004) PubMed · PMID 15134289
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction. (2003) PubMed · PMID 12851303
Dosing in Research Literature
In preclinical research, PT-141 has been administered systemically in various animal models to evaluate dose-dependent effects on erectile function and neuronal activation. The exact dosing regimens vary across studies, typically involving intravenous or subcutaneous routes to assess pharmacodynamic responses.
Clinical research has explored intranasal and subcutaneous dosing for PT-141, with doses titrated to evaluate efficacy and safety in sexual dysfunction. However, precise dosing ranges and protocols remain variable and are primarily established within clinical trial contexts rather than standardized research guidelines. Therefore, dosing information in research literature should be interpreted within the experimental framework without extrapolation to therapeutic use.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about PT-141
What is PT-141 and its FDA approval status?
PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist with an FDA-approved pharmaceutical form marketed as Vyleesi for treatment of hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 is distinct from the approved drug and is used solely for laboratory and preclinical studies.
What is PT-141 studied for in research?
PT-141 is primarily studied for its effects on sexual dysfunction, including erectile dysfunction and female sexual arousal disorders. It is used in research to understand melanocortin receptor-mediated pathways in sexual behavior and central nervous system regulation.
How does PT-141 work mechanistically?
PT-141 acts as an agonist at central melanocortin receptors MC3R and MC4R, activating neurons in the hypothalamus and related brain regions. This neuronal activation promotes sexual arousal and erectile function through central nervous system pathways rather than peripheral mechanisms.
Can PT-141 be combined with other peptides in research?
In research settings, PT-141 is sometimes studied in combination with peptides like Kisspeptin-10 or GHRP-6 to investigate interactive effects on neuroendocrine and sexual function pathways, offering broader insights into central regulation mechanisms.
How should PT-141 be stored and handled in research?
PT-141 should be stored according to manufacturer specifications, typically at low temperatures and protected from light to maintain stability. Handling should follow standard laboratory safety protocols for peptides, including use of appropriate personal protective equipment and avoiding contamination.
Legal & research status: PT-141 is an FDA-approved prescription drug (marketed as Vyleesi (bremelanotide)). Material sold as a research peptide is not the approved pharmaceutical product and is offered for laboratory and research use only, not for human consumption.